Accuray (ARAY) Projected to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY) will likely be releasing its Q4 2026 results after the market closes on Wednesday, August 12th. Analysts expect Accuray to post earnings of ($0.03) per share and revenue of $105.30 million for the quarter. Individuals may visit the the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, May 6th. The medical equipment provider reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). Accuray had a negative net margin of 10.76% and a negative return on equity of 79.43%. The business had revenue of $104.85 million for the quarter, compared to analyst estimates of $111.90 million.

Accuray Stock Down 3.6%

NASDAQ ARAY traded down $0.01 during trading hours on Wednesday, hitting $0.30. The company had a trading volume of 64,693 shares, compared to its average volume of 2,161,221. The firm’s 50 day moving average is $0.30 and its 200 day moving average is $0.43. The company has a debt-to-equity ratio of 3.21, a current ratio of 1.42 and a quick ratio of 0.66. Accuray has a fifty-two week low of $0.22 and a fifty-two week high of $2.10. The company has a market capitalization of $35.69 million, a price-to-earnings ratio of -0.81 and a beta of 1.39.

Institutional Investors Weigh In On Accuray

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in shares of Accuray in the 4th quarter valued at approximately $137,000. Invesco Ltd. grew its position in shares of Accuray by 52.7% during the fourth quarter. Invesco Ltd. now owns 245,000 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 84,528 shares in the last quarter. Mackenzie Financial Corp grew its position in shares of Accuray by 76.5% during the fourth quarter. Mackenzie Financial Corp now owns 1,918,086 shares of the medical equipment provider’s stock worth $1,538,000 after buying an additional 831,220 shares in the last quarter. Oxford Asset Management LLP bought a new stake in shares of Accuray in the fourth quarter worth $44,000. Finally, Bridgeway Capital Management LLC increased its stake in shares of Accuray by 34.8% in the fourth quarter. Bridgeway Capital Management LLC now owns 174,425 shares of the medical equipment provider’s stock worth $144,000 after buying an additional 45,025 shares during the last quarter. Institutional investors and hedge funds own 64.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ARAY. BTIG Research reiterated a “neutral” rating on shares of Accuray in a research note on Wednesday, July 8th. Weiss Ratings upgraded Accuray from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. Finally, Jefferies Financial Group downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $2.00.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.